Az Alzheimer-kór és a diabetes mellitus az életkorral növekvő gyakoriságú betegség. A demográfiai változások, az idősödő társadalmak tükrében külön-külön is népegészségügyi jelentőségű két kórkép között kapcsolat van. A kockázati tényezőket felmérő vizsgálatok alapján a 2-es típusú diabetes mellitus az Alzheimer-kór egyik kockázati faktorának tekinthető. Az Alzheimer-kór ma még korlátozottan befolyásolható betegség, ugyanakkor a diabetes mellitus optimális kezelése egyben az Alzheimer-kórt is kedvezően befolyásolhatja. A két betegség közötti kapcsolat ma még nem teljesen tisztázott, azonban a diabetes mellitus ismert vascularis hatásain túl, a neurodegeneratív folyamatot közvetlenül is befolyásoló központi idegrendszeri hatásokra is fény derült. Az utóbbi években feltárt centrális inzulinrezisztencia potenciális terápiája nemcsak az anyagcsere-betegségek, hanem az Alzheimer-kór kezelésében is ígéretes lehet. Orv. Hetil., 2011, 152, 512–515.
Reitz, C., Tang, M. X., Schupf, N. és mtsai: A summary risk score for the prediction of Alzheimer disease in elderly persons. Arch. Neurol., 2010, 67, 835–841.
Schupf N. , 'A summary risk score for the prediction of Alzheimer disease in elderly persons ' (2010 ) 67 Arch. Neurol. : 835 -841 .
Raina, P., Santaguida, P., Ismaila, A. és mtsai: Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann. Intern. Med., 2008, 148, 379–397.
Ismaila A. , 'Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline ' (2008 ) 148 Ann. Intern. Med. : 379 -397 .
Atri, A., Shaughnessy, L. W., Locascio, J. J. és mtsa: Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis. Assoc. Disord., 2008, 22, 209–221.
Locascio J. J. , 'Long-term course and effectiveness of combination therapy in Alzheimer disease ' (2008 ) 22 Alzheimer Dis. Assoc. Disord. : 209 -221 .
Kovacs, T.: Therapy of Alzheimer disease. Neuropsychopharmacol. Hung., 2009, 11, 27–33.
Kovacs T. , 'Therapy of Alzheimer disease ' (2009 ) 11 Neuropsychopharmacol. Hung. : 27 -33 .
Ott, A., Stolk, R. P., Pols, H. A. és mtsai: Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology, 1999, 53, 1937–1942.
Pols H. A. , 'Diabetes mellitus and the risk of dementia: The Rotterdam Study ' (1999 ) 53 Neurology : 1937 -1942 .
Peila, R., Rodriguez, B. L., Launer, L. J.: Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes, 2002, 51, 1256–1262.
Launer L. J. , 'Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study ' (2002 ) 51 Diabetes : 1256 -1262 .
Luchsinger, J. A., Tang, M. X., Stern, Y. és mtsai: Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort. Am. J. Epidemiol., 2001, 154, 635–641.
Stern Y. , 'Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort ' (2001 ) 154 Am. J. Epidemiol. : 635 -641 .
MacKnight, C., Rockwood, K., Awalt, E. és mtsa: Diabetes mellitus and the risk of dementia, Alzheimer’s disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement. Geriatr. Cogn. Disord., 2002, 14, 77–83.
Awalt E. , 'Diabetes mellitus and the risk of dementia, Alzheimer’s disease and vascular cognitive impairment in the Canadian Study of Health and Aging ' (2002 ) 14 Dement. Geriatr. Cogn. Disord. : 77 -83 .
Hassing, L. B., Johansson, B., Nilsson, S. E. és mtsai: Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer’s disease: a population-based study of the oldest old. Int. Psychogeriatr., 2002, 14, 239–248.
Nilsson S. E. , 'Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer’s disease: a population-based study of the oldest old ' (2002 ) 14 Int. Psychogeriatr. : 239 -248 .
Profenno, L. A., Porsteinsson, A. P., Faraone, S. V.: Meta-analysis of Alzheimer’s disease risk with obesity, diabetes, and related disorders. Biol. Psychiatry, 2010, 67, 505–512.
Faraone S. V. , 'Meta-analysis of Alzheimer’s disease risk with obesity, diabetes, and related disorders ' (2010 ) 67 Biol. Psychiatry : 505 -512 .
Arvanitakis, Z., Wilson, R. S., Bienias, J. L. és mtsai: Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch. Neurol., 2004, 61, 661–666.
Bienias J. L. , 'Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function ' (2004 ) 61 Arch. Neurol. : 661 -666 .
Helzner, E. P., Scarmeas, N., Cosentino, S. és mtsai: Survival in Alzheimer disease: a multiethnic, population-based study of incident cases. Neurology, 2008, 71, 1489–1495.
Cosentino S. , 'Survival in Alzheimer disease: a multiethnic, population-based study of incident cases ' (2008 ) 71 Neurology : 1489 -1495 .
Ahtiluoto, S., Polvikoski, T., Peltonen, M. és mtsai: Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology, 2010, 75, 1195–1202.
Peltonen M. , 'Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study ' (2010 ) 75 Neurology : 1195 -1202 .
Messier, C., Gagnon, M.: Cognitive decline associated with dementia and type 2 diabetes: the interplay of risk factors. Diabetologia, 2009, 52, 2471–2474.
Gagnon M. , 'Cognitive decline associated with dementia and type 2 diabetes: the interplay of risk factors ' (2009 ) 52 Diabetologia : 2471 -2474 .
Xu, W. L., Qiu, C. X., Winblad, B. és mtsai: Uncontrolled diabetes increases the risk of Alzheimer’s disease: a population-based cohort study. Diabetologia, 2009, 52, 1031–1039.
Winblad B. , 'Uncontrolled diabetes increases the risk of Alzheimer’s disease: a population-based cohort study ' (2009 ) 52 Diabetologia : 1031 -1039 .
Benedict, C., Hallschmid, M., Schmitz, K. és mtsai: Intranasal insulin improves memory in humans: superiority of insulin aspart. Neuropsychopharmacology, 2007, 32, 239–243.
Schmitz K. , 'Intranasal insulin improves memory in humans: superiority of insulin aspart ' (2007 ) 32 Neuropsychopharmacology : 239 -243 .
Gold, S. M., Dziobek, I., Sweat, V. és mtsai: Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes. Diabetologia, 2007, 50, 711–719.
Sweat V. , 'Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes ' (2007 ) 50 Diabetologia : 711 -719 .
Halmos T., Suba I.: Az agy szerepe az anyagcsere és energiaforgalom szabályozásában: az inzulin központi idegrendszeri hatásai, az agy inzulinrezisztenciája. Orv. Hetil., 2011, 152, 83–91.
Suba I. , 'Az agy szerepe az anyagcsere és energiaforgalom szabályozásában: az inzulin központi idegrendszeri hatásai, az agy inzulinrezisztenciája ' (2011 ) 152 Orv. Hetil. : 83 -91 .
Craft, S.: Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis. Assoc. Disord., 2006, 20, 298–301.
Craft S. , 'Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications ' (2006 ) 20 Alzheimer Dis. Assoc. Disord. : 298 -301 .
Jiang, Q., Heneka, M., Landreth, G. E.: The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer’s disease: therapeutic implications. CNS Drugs, 2008, 22, 1–14.
Landreth G. E. , 'The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer’s disease: therapeutic implications ' (2008 ) 22 CNS Drugs : 1 -14 .
Risner, M. E., Saunders, A. M., Altman, J. F. és mtsai: Efficacy of rosiglitazone in a genetically defined population with mild-tomoderate Alzheimer’s disease. Pharmacogenomics J., 2006, 6, 246–254.
Altman J. F. , 'Efficacy of rosiglitazone in a genetically defined population with mild-tomoderate Alzheimer’s disease ' (2006 ) 6 Pharmacogenomics J. : 246 -254 .
McClean, P. L., Gault, V. A., Harriott, P. és mtsa: Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer’s disease. Eur. J. Pharmacol., 2010, 630, 158–162.
Harriott P. , 'Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer’s disease ' (2010 ) 630 Eur. J. Pharmacol. : 158 -162 .
Zhong, Y., Li, S. H., Liu, S. M. és mtsai: Reactive protein upregulates receptor for advanced glycation end products expression in human endothelial cells. Hypertension, 2006, 48, 504–511.
Liu S. M. , 'Reactive protein upregulates receptor for advanced glycation end products expression in human endothelial cells ' (2006 ) 48 Hypertension : 504 -511 .
Valente, T., Gella, A., Fernandez-Busquets, X. és mtsai: Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer’s disease and diabetes mellitus. Neurobiol. Dis., 2010, 37, 67–76.
Fernandez-Busquets X. , 'Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer’s disease and diabetes mellitus ' (2010 ) 37 Neurobiol. Dis. : 67 -76 .